AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20393355 — intervention group
Group type: EXPERIMENTAL
Intervention: Power forwards and centers
Number of subjects: 45
Study 18759980 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 44
Study 18759980 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital
Number of subjects: 44
Study 16013911 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz or 5 Hz)
Number of subjects: 30
Study 16013911 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study 12432178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC; 60 g day-1)
Number of subjects: 13
Study 12432178 — intervention group
Group type: COMPARATOR
Intervention: Concentrated whey protein powder (WP; 60 g day-1)
Number of subjects: 13
Study 10839068 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured teaching intervention on RN delegation decision making
Number of subjects: 0
Study 8947821 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ham's F10 medium (MM)
Number of subjects: 0
Study 8947821 — intervention group
Group type: COMPARATOR
Intervention: Modified Ham's F10 medium with 0.5 mM glucose (LGMM)
Number of subjects: 0
Study 8947821 — intervention group
Group type: COMPARATOR
Intervention: Normal Ham's F10
Number of subjects: 0
Study 1471582 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 109
Study 1471582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1,000 IU of vitamin A)
Number of subjects: 109
Study 6744778 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg HCTZ/amiloride 2.5 mg
Number of subjects: 30
Study 6744778 — intervention group
Group type: COMPARATOR
Intervention: 25 mg HCTZ alone
Number of subjects: 30
Study 6744778 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg HCTZ/amiloride 2.5 mg (higher dose)
Number of subjects: 30
Study 30702519 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily protein-calorie supplement and micronutrient supplement
Number of subjects: 74
Study 30702519 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient supplement only
Number of subjects: 74
Study 30201853 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 g Casein Protein (CP)
Number of subjects: 9
Study 30201853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 30201853 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g Casein Protein (CP)
Number of subjects: 9
Study 30201853 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g Whey Protein (WP)
Number of subjects: 9
Study 30201853 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 g Whey Protein (WP)
Number of subjects: 9
Study 26890094 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated continuous theta burst stimulation (cTBS) over the left primary auditory cortex
Number of subjects: 23
Study 26890094 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 23
Study 26890094 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated continuous theta burst stimulation (cTBS)
Number of subjects: 23
Study 24650926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic pressure-guided treatment (active, n=23)
Number of subjects: 50
Study 24650926 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control, n=27)
Number of subjects: 50
Study 24650926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active and control)
Number of subjects: 50
Study 24650926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic pressure-guided treatment (active)
Number of subjects: 50
Study 22956578 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA1 purified from IgAN patients
Number of subjects: 0
Study 22956578 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-aggregated IgA1 purified from IgAN patients
Number of subjects: 0
Study 22956578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of SYK
Number of subjects: 0
Study 22956578 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of SYK by small interfering RNA
Number of subjects: 0
Study 19858314 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for fruit consumption
Number of subjects: 0
Study 19858314 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for vegetable consumption
Number of subjects: 0
Study 19858314 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy efficacy to influence parents to make FV available
Number of subjects: 0
Study 19858314 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy efficacy to influence after-school staff to make FV available
Number of subjects: 0
Study 19858314 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement invariance across gender, SES, and ethnicity
Number of subjects: 0
Study 19858314 — intervention group
Group type: EXPERIMENTAL
Intervention: Population heterogeneity tests
Number of subjects: 0
Study 17870636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0
Study 17870636 — intervention group
Group type: COMPARATOR
Intervention: 3-day oral quinine-clindamycin
Number of subjects: 0
Study 16216093 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 104
Study 16216093 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CA)
Number of subjects: 104
Study 16216093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulphate (FS)
Number of subjects: 104
Study 12244905 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent occlusive dressing applied to the insertion site, not removed for 7 days unless signs of local infection (Group I)
Number of subjects: 72
Study 12244905 — intervention group
Group type: COMPARATOR
Intervention: Daily site care with povidone-iodine 10% solution and new sterile gauze (Group II)
Number of subjects: 72
Study 12244905 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion site infection
Number of subjects: 72
Study 12244905 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 60 years
Number of subjects: 72
Study 12244905 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition administration
Number of subjects: 72
Study 12244905 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting malignancy or diabetes mellitus, duration of catheter, antibiotics use
Number of subjects: 72
Study 10416046 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg bid
Number of subjects: 23
Study 10416046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7580834 — intervention group
Group type: EXPERIMENTAL
Intervention: HGP‐30 vaccine (10 and 25 micrograms/kg)
Number of subjects: 38
Study 7580834 — intervention group
Group type: EXPERIMENTAL
Intervention: HGP‐30 vaccine (50 and 100 micrograms/kg)
Number of subjects: 38
Study 7580834 — intervention group
Group type: EXPERIMENTAL
Intervention: HGP‐30 vaccine
Number of subjects: 38
Study 7580834 — intervention group
Group type: COMPARATOR
Intervention: Non-immunized subject
Number of subjects: 38
Study 2164934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole tablets every 8 hours for six doses
Number of subjects: 24
Study 2164934 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch
Number of subjects: 24
Study 2164934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ketoconazole and transdermal estradiol
Number of subjects: 24
Study 2164934 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive)
Number of subjects: 24
Study 6942844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 10
Study 6942844 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate
Number of subjects: 10
Study 6942844 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Gemfibrozil and Clofibrate
Number of subjects: 10
Study 31865749 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including prior relationships with local health department, alignment of project goals with practice priorities, and monetary incentives.
Number of subjects: 257
Study 31865749 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies including ongoing multifaceted communication strategy.
Number of subjects: 257
Study 31422390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus antibiotic
Number of subjects: 60
Study 31422390 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic and placebo (Control)
Number of subjects: 60
Study 29525907 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of 10 mg/ml triamcinolone (steroid)
Number of subjects: 9
Study 29525907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of 1 ml autologous platelet-rich plasma (PRP)
Number of subjects: 9
Study 29525907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (PRP and ILS)
Number of subjects: 9
Study 26574953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg od)
Number of subjects: 12
Study 26574953 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 mg od)
Number of subjects: 12
Study 24964392 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat fixed-dose combination (FDC) 800 mg/150 mg
Number of subjects: 133
Study 24964392 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat FDC with high-fat breakfast
Number of subjects: 133
Study 24964392 — intervention group
Group type: COMPARATOR
Intervention: Darunavir (800 mg) and cobicistat (150 mg) as single agents
Number of subjects: 133
Study 24964392 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to darunavir
Number of subjects: 133
Study 24964392 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to cobicistat
Number of subjects: 133
Study 22368231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment with methotrexate after 1 g infusion on days 1 and 15
Number of subjects: 111
Study 22368231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment in rheumatoid factor-positive patients
Number of subjects: 111
Study 22368231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of V allele carriage
Number of subjects: 111
Study 20022717 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy by mothers plus skin‐to‐skin care (Intervention Group)
Number of subjects: 73
Study 20022717 — intervention group
Group type: COMPARATOR
Intervention: Skin‐to‐skin care (Control Group)
Number of subjects: 73
Study 17404083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole treatment
Number of subjects: 103
Study 16334808 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 25 microg b.i.d. and cimetidine 400 mg b.i.d. for 8 weeks
Number of subjects: 171
Study 16334808 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg b.i.d. alone for 8 weeks
Number of subjects: 171
Study 12494804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ilioinguinal nerve block with 15 ml x 2 of 0.25% bupivacaine
Number of subjects: 60
Study 12494804 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous 1 mg kg‐1 of tramadol
Number of subjects: 60
Study 9798447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Richards screws
Number of subjects: 268
Study 9798447 — intervention group
Group type: COMPARATOR
Intervention: 2 Uppsala screws
Number of subjects: 268
Study 7710022 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation with a laryngeal mask
Number of subjects: 40
Study 7710022 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation with a tracheal tube
Number of subjects: 40
Study 2534416 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nicorandil
Number of subjects: 12
Study 2534416 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nicorandil
Number of subjects: 12
Study 2534416 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicorandil
Number of subjects: 12
Study 16256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 0
Study 16256 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide
Number of subjects: 0
Study 31289887 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation during training
Number of subjects: 32
Study 31289887 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation during training
Number of subjects: 32
Study 31289887 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 32
Study 31289887 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 32
Study 28603907 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed bronchoscopy simulator
Number of subjects: 30
Study 28603907 — intervention group
Group type: COMPARATOR
Intervention: Commercially available bronchial tree simulators
Number of subjects: 30
Study 25722380 — intervention group
Group type: EXPERIMENTAL
Intervention: trabectedin + PLD
Number of subjects: 264
Study 25722380 — intervention group
Group type: COMPARATOR
Intervention: PLD
Number of subjects: 264
Study 23812516 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant cereal A
Number of subjects: 19
Study 23812516 — intervention group
Group type: COMPARATOR
Intervention: Infant cereal B
Number of subjects: 19
Study 20685043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg IV cortisol infusion
Number of subjects: 27
Study 20685043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19333947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40-80 mg/day)
Number of subjects: 0
Study 19333947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16705579 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 428
Study 15462107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 15
Study 15462107 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 15
Study 11345280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 26
Study 11345280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 26
Study 11345280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 26
Study 11345280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9404206 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 kV (with grid)
Number of subjects: 25078
Study 9404206 — intervention group
Group type: COMPARATOR
Intervention: 25 kV (no grid)
Number of subjects: 25078
Study 7694321 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 127
Study 7694321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-chemotherapy
Number of subjects: 127
Study 7694321 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 127
Study 3308728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal silicone oil
Number of subjects: 0
Study 3308728 — intervention group
Group type: COMPARATOR
Intervention: Gas (20% C3F8 or 30% C4F8)
Number of subjects: 0
Study 28960913 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 0
Study 28960913 — intervention group
Group type: EXPERIMENTAL
Intervention: Household socioeconomic status, birth outcomes, child growth, maternal and child morbidity
Number of subjects: 0
Study 28960913 — intervention group
Group type: EXPERIMENTAL
Intervention: Heads of household
Number of subjects: 0
Study 28960913 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal experience using SQ-LNS
Number of subjects: 0
Study 27571371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed labial appliances
Number of subjects: 44
Study 27571371 — intervention group
Group type: COMPARATOR
Intervention: Clear aligners (Invisalign)
Number of subjects: 44
Study 24630479 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program (10 sessions)
Number of subjects: 53
Study 24630479 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 students and 10 professionals)
Number of subjects: 53
Study 23571496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated filgrastim 100 µg/kg
Number of subjects: 337
Study 23571496 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim 5 µg/kg/day
Number of subjects: 337
Study 23571496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated filgrastim
Number of subjects: 337
Study 23571496 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 337
Study 20033901 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief problem-solving treatment by primary care doctors (PST-PC)
Number of subjects: 299
Study 20033901 — intervention group
Group type: COMPARATOR
Intervention: Group video-viewing (placebo)
Number of subjects: 299
Study 18248543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based exercise program (10-week duration)
Number of subjects: 68
Study 18248543 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (control)
Number of subjects: 68
Study 16919061 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication overuse headache (MOH)
Number of subjects: 60
Study 16919061 — intervention group
Group type: COMPARATOR
Intervention: Analgesics
Number of subjects: 60
Study 16919061 — intervention group
Group type: COMPARATOR
Intervention: Triptan-induced medication overuse headache (MOH)
Number of subjects: 60
Study 16919061 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study 16919061 — intervention group
Group type: COMPARATOR
Intervention: Episodic migraine
Number of subjects: 60
Study 16919061 — intervention group
Group type: COMPARATOR
Intervention: Depression without headache
Number of subjects: 60
Study 15265052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (3 sessions)
Number of subjects: 40
Study 15265052 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 hyperbaric air treatments)
Number of subjects: 40
Study 15265052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 40
Study 15265052 — intervention group
Group type: COMPARATOR
Intervention: Control group (hyperbaric air treatments)
Number of subjects: 40
Study 11413265 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM)
Number of subjects: 168
Study 11413265 — intervention group
Group type: COMPARATOR
Intervention: Face to face (FF)
Number of subjects: 168
Study 9255753 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest 50
Number of subjects: 43
Study 9255753 — intervention group
Group type: COMPARATOR
Intervention: Systen 50 (Evorel 50)
Number of subjects: 43
Study 8331200 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg
Number of subjects: 24
Study 8331200 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 40 mg
Number of subjects: 24
Study 8331200 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 80 mg
Number of subjects: 24
Study 8331200 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose administration of 40 mg/day for 5 days
Number of subjects: 24
Study 8331200 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose administration of 80 mg/day for 5 days
Number of subjects: 24
Study 8331200 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose administration of 160 mg/day for 5 days
Number of subjects: 24
Study 3571773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized bitolterol mesylate (0.2%)
Number of subjects: 183
Study 3571773 — intervention group
Group type: COMPARATOR
Intervention: Nebulized isoproterenol hydrochloride (0.3%)
Number of subjects: 183
Study 31244992 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (n = 49) applied from L3-S1 at a frequency of 65-100 Hz, pulse width of 100-200 usec, turned on 2 min before and maintained during the self-paced walking test (SPWT).
Number of subjects: 104
Study 31244992 — intervention group
Group type: COMPARATOR
Intervention: De-tuned TENS (n = 51) applied similarly for 30 s followed by ramping down to zero stimulus, turned off before and during the SPWT.
Number of subjects: 104
Study 28970147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans (0.5 g/kg; maximum, 19 g)
Number of subjects: 23
Study 28970147 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 23
Study 28970147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans
Number of subjects: 23
Study 28970147 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin
Number of subjects: 23
Study 26169710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalad-caudad blunt expansion
Number of subjects: 112
Study 26169710 — intervention group
Group type: COMPARATOR
Intervention: Transverse blunt expansion
Number of subjects: 112
Study 25205759 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial aspiration (EA)
Number of subjects: 300
Study 25205759 — intervention group
Group type: COMPARATOR
Intervention: Non-endometrial aspiration (non-EA)
Number of subjects: 300
Study 22684198 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise (IE)
Number of subjects: 40
Study 22684198 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistive exercise (PRE)
Number of subjects: 40
Study 20414673 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia (simulated altitude of 4,500 m)
Number of subjects: 23
Study 18008246 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine prophylaxis
Number of subjects: 1437
Study 16344230 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based attenuation correction (AC)
Number of subjects: 118
Study 16344230 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT images with AC
Number of subjects: 118
Study 16344230 — intervention group
Group type: COMPARATOR
Intervention: SPECT images without AC
Number of subjects: 118
Study 12492188 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg p.o. b.i.d. for 6 weeks
Number of subjects: 140
Study 12492188 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules p.o. b.i.d. for 6 weeks
Number of subjects: 140
Study 9804720 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 109